NCT07400484Recruiting
Differences in N-CAD Concentration and Brain Function Between Children With ASD and TD
A Study on the Differences in N-CAD Concentration and Brain Function Between Children With Autism Spectrum Disorder and Typically Developing Children
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
The incidence of autism spectrum disorders is increasing, about 1 / 36. Neural cadherin (NCAD) is closely related to synaptic structure and function. The cdh2 gene encoding NCAD has been shown to be associated with a variety of neurodevelopmental diseases and is one of the six risk genes for ASD. Functional near-infrared spectroscopy (fNIRS) is a neuroimaging technology that uses the principle of near-infrared spectroscopy to detect the functional activation of human cortex. The application of fNIRS to explore the neural mechanism of children with ASD has developed rapidly. It has the advantages of non-invasive, portable, relatively low cost and unlimited physical activity. And for ASD children, their command compliance and self-control are relatively low, so fNIRS is more widely used in ASD children. According to dsm-5 standard, we recruited ASD children and TD children, collected their peripheral blood, and detected the plasma n-cad concentration. At the same time, the resting state of fNIRS of the two groups of children was collected, and the ultra scan monitoring was carried out simultaneously during Gesell assessment. The purpose of this study was to explore the difference of peripheral blood NCAD concentration between preschool ASD children and TD children and the difference of brain function in resting state and social interaction state. And the relationship between the characteristics of brain function and the level of cognitive development in children with ASD.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 98 (estimated)
- First submitted
- 25 Jan 2026
- Start date
- 18 Dec 2025
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- Chen Li
- Diseases
- Autism
- NCT number
- NCT07400484
What you commit to
- Study type: Observational
- Planned participants: 98
- From 18 Dec 2025 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis or manifestation of genetic diseases or syndromes related to ASD (such as Rett syndrome);
- Medical or nervous system diseases affecting growth, development or cognition (such as central nervous system infection, epilepsy, congenital heart disease, etc.);
- Sensory impairment such as vision or hearing loss;
Age
- Low birth weight (birth weight \<2000 g) or preterm birth (gestational age \<37 weeks);
Other
- Adopted children;
- Parents refused to sign the informed consent form;
- Other researchers consider it inappropriate to participate in the study.
Who the study is looking for
- Age at enrollment ≥ 3 years and \<5 years;
- The diagnosis was made by 2 developmental behavioral pediatricians or child psychiatrists with vice senior titles or above, and the history and clinical manifestations were in line with ASD and ICD-11 diagnostic criteria for ASD; .
Age in the registry: 3 years to 5 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Growth, Development and Mental health of Children and Adolescence Center Coordinator of this site? Confirm its status | Chongqing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.